FibroBiologics completed manufacturing and site onboarding for its phase 1/2 trial of CYWC628 to treat diabetic foot ulcers, aiming to dose the first patient in Q2 2026. The company reported positive preclinical results for burn and degenerative disc disease programs, expanded its patent portfolio, and raised $3 million through a direct offering. Financially, FibroBiologics posted a $5 million net loss for Q1 2026, with increased R&D expenses due to clinical trial preparations. Upcoming milestones include interim trial results in Q3 2026 and IND submissions for psoriasis and multiple sclerosis treatments later in the year.
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
